A privately-owned rare disease biotech preparing for a global Phase 3 clinical trial faced significant contract challenges with its CRO. Misaligned terms created limited leverage to enforce performance, slow responsiveness to operational issues, and exposure to budget overruns. Seuss+ was engaged to renegotiate contracts, protect the sponsor’s position, and establish governance structures to hold the CRO accountable.
A privately-owned biotechnology company, backed by over £270M in private financing, was running a complex global Phase 3 rare disease study with strict inclusion criteria. Nearly a year into recruitment, only 45 of 150 sites were activated and just 7 of 225 patients enrolled. With increasing board concerns over trial feasibility, Seuss+ was brought in to stabilize recruitment and restore confidence in the study’s success.
A high-potential biotech, entering Phase 2 with an ambitious formulation study, faced late-stage strategic changes that rendered its original CRO unsuitable. Operating with a lean team and under competitive pressures, the sponsor required rapid CRO transition, complete vendor oversight, and embedded operational expertise to stay on schedule and protect data integrity.
We can help you